Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 7

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)

Ragamin, Aviël, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A, Fieten, Karin B, van Mierlo, Minke M F, Bronner, Madelon B, Romeijn, Geertruida L E, Sloot, Manon M, Boesjes, Celeste M, van der Rijst, Lisa P, Arents, Bernd W M, Rustemeyer, Thomas, Schuttelaar, Marie L A, Pasmans, Suzanne G M A · 2024 · British Journal of Dermatology

Abstract

Background: Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation; however, its role in the management of AD remains poorly understood. Objectives: To investigate the effectiveness of antibacterial therapeutic clothing + standard topical treatment in patients with moderate-to-severe AD vs. standard therapeutic clothing + standard topical treatment; and, if effectiveness was demonstrated, to demonstrate its cost-effectiveness. Methods: A pragmatic double-blinded multicentre randomized controlled trial (NCT04297215) was conducted in patients of all ages with moderate-to-severe AD. Patients were centrally randomized 1 : 1 : 1 to receive standard therapeutic clothing or antibacterial clothing based on chitosan or silver. The primary outcome was the between-group difference in Eczema Area and Severity Index (EASI) measured over 52 weeks. Secondary outcomes included patient-reported outcomes (PROs), topical corticosteroid (TCS) use, SA colonization, safety and cost-effectiveness. Outcomes were assessed by means of (generalized) linear mixed-model analyses. Results: Between 16 March 2020 and 20 December 2021, 171 patients were enrolled. In total, 159 patients were included (54 in the standard therapeutic clothing group, 50 in the chitosan group and 55 in the silver group). Adherence was high [median 7 nights a week wear (interquartile range 3–7)]. Median EASI scores at baseline and at 4, 12, 26 and 52 weeks were 11.8, 4.3, 4.6, 4.2 and 3.6, respectively, in the standard therapeutic clothing group vs. 11.3, 5.0, 3.0, 3.0 and 4.4, respectively, in the chitosan group, and 11.6, 5.0, 5.4, 4.6 and 5.8, respectively, in the silver group. No differences in EASI over 52 weeks between the standard therapeutic clothing group, the chitosan group [–0.1, 95% confidence interval (CI) –0.3 to 0.2; P = 0.53] or the silver group (–0.1, 95% CI –0.3 to 0.2; P = 0.58) were found. However, a small significant group × time interaction effect between the standard and silver groups was found (P = 0.03), in which the silver group performed worse after 26 weeks. No differences between groups were found in PROs, TCS use, SA skin colonization and healthcare utilization. No severe adverse events or silver absorption were observed. Conclusions: The results of this study suggest no additional benefits of antibacterial agents in therapeutic clothing in patients with moderate-to-severe AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bjd/ljad437

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 45

  1. Langan, 2020, Atopic dermatitis, Lancet, 396, 345, 10.1016/S0140-6736(20)31286-1 · DOI · Paper page
  2. Wollenberg, 2022, European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations, J Eur Acad Dermatol Venereol, 36, 1904, 10.1111/jdv.18429 · DOI · Paper page
  3. Anderson, 2021, Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis, Dermatol Ther (Heidelb, 11, 1571, 10.1007/s13555-021-00580-2 · DOI
  4. Ring, 2012, Guidelines for treatment of atopic eczema (atopic dermatitis) part I, J Eur Acad Dermatol Venereol, 26, 1045, 10.1111/j.1468-3083.2012.04635.x · DOI · Paper page
  5. Zhang, 2003, Antibacterial properties of cotton fabrics treated with chitosan, Text Res J, 73, 1103, 10.1177/004051750307301213 · DOI · Paper page
  6. Lansdown, 2006, Silver in health care: antimicrobial effects and safety in use, Curr Probl Dermatol, 33, 17, 10.1159/000093928 · DOI · Paper page
  7. Totté, 2016, Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis, Br J Dermatol, 175, 687, 10.1111/bjd.14566 · DOI · Paper page
  8. Nyst, 2015, Antibacteriële verbandkleding bij constitutioneel eczeem
  9. Ragamin, 2021, The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trial, Trials, 22, 902, 10.1186/s13063-021-05836-y · DOI
  10. Williams, 1994, The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation, Br J Dermatol, 131, 406, 10.1111/j.1365-2133.1994.tb08532.x · DOI · Paper page
  11. Chopra, 2017, Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis, Br J Dermatol, 177, 1316, 10.1111/bjd.15641 · DOI · Paper page
  12. Williams, 2022, The HOME core outcome set for clinical trials of atopic dermatitis, J Allergy Clin Immunol, 149, 1899, 10.1016/j.jaci.2022.03.017 · DOI · Paper page
  13. Simpson, 2020, The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis, J Am Acad Dermatol, 83, 839, 10.1016/j.jaad.2020.04.104 · DOI · Paper page
  14. Ragamin, 2023, Investigator Global Assessment for impetiginization in atopic dermatitis (IGA impetiginization): development and initial reliability testing, Br J Dermatol, 189, 129, 10.1093/bjd/ljad085 · doi:10.1093/bjd/ljad085
  15. Charman, 2004, The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective, Arch Dermatol, 140, 1513, 10.1001/archderm.140.12.1513 · DOI · Paper page
  16. Yosipovitch, 2019, Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis, Br J Dermatol, 181, 761, 10.1111/bjd.17744 · DOI · Paper page
  17. Finlay, 1994, Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x · DOI · Paper page
  18. Lewis-Jones, 1995, The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use, Br J Dermatol, 132, 942, 10.1111/j.1365-2133.1995.tb16953.x · DOI · Paper page
  19. Lewis-Jones, 2001, The Infants’ Dermatitis Quality of Life Index, Br J Dermatol, 144, 104, 10.1046/j.1365-2133.2001.03960.x · DOI · Paper page
  20. Howells, 2020, Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP), Br J Dermatol, 183, 524, 10.1111/bjd.18780 · DOI
  21. Bowie, 2022, Agreement and correlation between different topical corticosteroid potency classification systems, JAMA Dermatol, 158, 796, 10.1001/jamadermatol.2022.1706 · doi:10.1001/jamadermatol.2022.1706
  22. Fluhr, 2010, Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study, Exp Dermatol, 19, e9-15, 10.1111/j.1600-0625.2009.00943.x · DOI
  23. Gauger, 2003, Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema, Dermatology, 207, 15, 10.1159/000070935 · DOI
  24. Ricci, 2004, Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis, Br J Dermatol, 150, 127, 10.1111/j.1365-2133.2004.05705.x · DOI
  25. Ricci, 2006, Evaluation of the antibacterial activity of a special silk textile in the treatment of atopic dermatitis, Dermatology, 213, 224, 10.1159/000095040 · doi:10.1159/000095040
  26. Yokoyama, 2009, Ethylene vinyl alcohol (EVOH) fiber compared to cotton underwear in the treatment of childhood atopic dermatitis: a double-blind randomized study, Indian Pediatr, 46, 611
  27. Fontanini, 2013, DermaSilk in long-term control of infantile atopic dermatitis: a double blind randomized controlled trial, G Ital Dermatol Venereol, 148, 293
  28. Stinco, 2008, A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis, Dermatology, 217, 191, 10.1159/000141648 · DOI
  29. Koller, 2007, Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial, Pediatr Allergy Immunol, 18, 335, 10.1111/j.1399-3038.2006.00511.x · doi:10.1111/j.1399-3038.2006.00511.x
  30. Park, 2012, A pilot study of silver-loaded cellulose fabric with incorporated seaweed for the treatment of atopic dermatitis, Clin Exp Dermatol, 37, 512, 10.1111/j.1365-2230.2011.04273.x · doi:10.1111/j.1365-2230.2011.04273.x
  31. Gauger, 2006, Silver-coated textiles in the therapy of atopic eczema, Curr Probl Dermatol, 33, 152, 10.1159/000093942 · DOI
  32. Juenger, 2006, Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD), Curr Med Res Opin, 22, 739, 10.1185/030079906X99990 · doi:10.1185/030079906x99990
  33. Araújo, 2013, A proposal for the use of new silver-seaweed-cotton fibers in the treatment of atopic dermatitis, Cutan Ocul Toxicol, 32, 268, 10.3109/15569527.2013.775655 · DOI
  34. Thomas, 2017, Silk garments plus standard care compared with standard care for treating eczema in children: a randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial), PLOS MED, 14, e1002280, 10.1371/journal.pmed.1002280 · DOI
  35. Oakes, 2017, Sample size, statistical power, and false conclusions in infant looking-time research, Infancy, 22, 436, 10.1111/infa.12186 · DOI · Paper page
  36. 2019, The importance of no evidence, Nat Hum Behav, 3, 197, 10.1038/s41562-019-0569-7 · DOI
  37. Tamai, 2023, Pathogenic role of the staphylococcal accessory gene regulator quorum sensing system in atopic dermatitis, Front Cell Infect Microbiol, 13, 1178650, 10.3389/fcimb.2023.1178650 · DOI
  38. George, 2019, Interventions to reduce Staphylococcus aureus in the management of eczema, Cochrane Database Syst Rev, 10, CD003871
  39. Nilsson, 1992, Topical corticosteroids and Staphylococcus aureus in atopic dermatitis, J Am Acad Dermatol, 27, 29, 10.1016/0190-9622(92)70151-5 · DOI · Paper page
  40. Höfer, 2018, A real-life based evaluation of the effectiveness of antibacterial fabrics in treating atopic dermatitis, Dermatol Res Pract, 2018, 7043438, 10.1155/2018/7043438 · DOI
  41. Niemeyer-van der Kolk, 2022, Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial, J Am Acad Dermatol, 86, 854, 10.1016/j.jaad.2020.08.132 · DOI
  42. Kim, 2019, Interactions between atopic dermatitis and Staphylococcus aureus infection: clinical implications, Allergy Asthma Immunol Res, 11, 593, 10.4168/aair.2019.11.5.593 · DOI · Paper page
  43. Kobayashi, 2015, Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis, Immunity, 42, 756, 10.1016/j.immuni.2015.03.014 · DOI · Paper page
  44. Perrelli, 1992, Tentative reference values for gold, silver and platinum: literature data analysis, Sci Total Environ, 120, 93, 10.1016/0048-9697(92)90219-I · DOI · Paper page
  45. Pluut, 2015, Percutaneous penetration of silver from a silver containing garment in healthy volunteers and patients with atopic dermatitis, Toxicol Lett, 235, 116, 10.1016/j.toxlet.2015.03.014 · DOI

Cited by

Metadata

Authors
Ragamin, A., Schappin, R., de Graaf, M., Tupker, R. A., Fieten, K. B., van Mierlo, M. M. F., Bronner, M. B., Romeijn, G. L. E., Sloot, M. M., Boesjes, C. M., van der Rijst, L. P., Arents, B. W. M., Rustemeyer, T., Schuttelaar, M. L. A., & Pasmans, S. G. M. A.
Affiliations
  • Department of Dermatology, Erasmus MC University Medical Center , Rotterdam , the Netherlands
  • Department of Dermatology and Allergology, University Medical Center Utrecht , Utrecht , the Netherlands
  • Department of Dermatology, St. Antonius Hospital , Nieuwegein , the Netherlands
  • Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich , Davos Wolfgang , Switzerland
  • Department of Dermatology, University Medical Center Groningen, University of Groningen , Groningen , the Netherlands
  • Dutch Association for People with Atopic Dermatitis , Nijkerk , the Netherlands
  • Department of Dermatology and Allergology, Amsterdam University Medical Centers , Amsterdam , the Netherlands
Venue
British Journal of Dermatology
Published
2023-11-04
Volume
190
Issue
3
Pages
342-354
ISSN
  • 0007-0963
  • 1365-2133
Cited by
7
References
3
Language
en
Funders
  • Netherlands Organization for Health Research and Development (843004017)
  • Ministry of Health, Welfare and Sport
  • National Health Care Institute of the Netherlands
  • Department of Dermatology of the Erasmus MC University Medical Centre Rotterdam

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.